home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

IBC's Targeting Metabolic Syndrome

 
  January 09, 2004  
     
 
-, Hilton Logan Airport, Boston, MA
May 3-5, 2004


IBC’s Targeting Metabolic Syndrome brings together industry and academic researchers working to reveal new targets for these diseases. Discussion will focus on the development of therapeutic prospects for controlling the set of early risk factors that can develop into Metabolic Syndrome. Updates from our marquis faculty will include the phenomena of Metabolic Syndrome and the potential for single therapeutic agents; clinical studies of high HDL cholesterol and its relationship to Metabolic Syndrome; new PPAR agonists and their impact on animal models of T2D and obesity; potential indications in metabolic diseases of the anticonvulsants Topiramate and Zonisamide; and new animal models for discovery and validation of novel therapeutic targets. Plus, be sure to join us for our pre-conference workshop that surveys novel tools and technologies for metabolic syndrome research. For up-to-date information on this event and to register, visit www.LifeSciencesInfo.com/metabolic.
 
 
Organized by: IBC Liffe Sciences
Invited Speakers: Keynote Presentation:
Jose Caro, M.D., Vice President Endocrine Research and Clinical Investigation, Eli Lilly and Company
 
Deadline for Abstracts: -
 
Registration: Phone: (508) 616-5550 x1004 Fax: (508) 616-5522 Email: reg@ibcusa.com Online: www.LifeSciencesInfo.com/metabolic
E-mail: reg@ibcusa.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.